The image shows the compound Tat-P4-(C5)2 after an injection into the spinal cord. The compound (purple) penetrates the nerve cells of the spinal cord (yellow), but not the surrounding cells (the cell nuclei are blue). Credit: University of Copenhagen.
Researchers from the University of Copenhagen have developed a new way to treat chronic pain which has been tested in mice. With a compound designed and developed by the researchers themselves, they can achieve complete pain relief.
Between seven and ten percent of the world’s population suffers from chronic pain originating from nerves that have been damaged. A disease that can be severely debilitating. Now, researchers from the University of Copenhagen have found a new way to treat the pain.
The treatment has been tested in mice, and the new results have been published in the scientific journal EMBO Molecular Medicine. For more than a decade, the researchers have been working to design, develop and test a drug that shall provide complete pain relief.
“We have developed a new way to treat chronic pain. It is a targeted treatment. That is, it does not affect the general neuronal signalling, but only affects the nerve changes that are caused by the disease,” says co-author Kenneth Lindegaard Madsen, Associate Professor at the Department of Neuroscience, University of Copenhagen.
“We have been working on this for more than ten years. We have taken the process all the way from understanding the biology, inventing and designing the compound to describing how it works in animals, affects their behaviour and removes the pain,” says Kenneth Lindegaard Madsen.
Chronic pain can occur, among other things, after surgery, in people with diabetes, after a blood clot and after an amputation in the form of phantom pain.
Clinical trials as the next step
The compound developed by the researchers is a so-called peptide named Tat-P4-(C5)2. The peptide is targeted and only affects the nerve changes that pose a problem and cause the pain.
In a previous study, the researchers have shown in an animal model that use of the peptide can also reduce addiction. Therefore, the researchers hope that the compound may potentially help pain patients who have become addicted to, for example, opioid pain relievers in particular.
“The compound works very efficiently, and we do not see any side effects. We can administer this peptide and obtain complete pain relief in the mouse model we have used, without the lethargic effect that characterises existing pain-relieving drugs,” says Kenneth Lindegaard Madsen, adding:
“Now, our next step is to work towards testing the treatment on people. The goal, for us, is to develop a drug, therefore the plan is to establish a biotech company as soon as possible so we can focus on this.”
The researchers are now working towards clinical trials in collaboration with, among others, pain researcher Nanna Brix Finnerup, Professor at Aarhus University.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- ‘Brain fog and daily medication’: Perth woman’s debilitating illness leaves her in ‘constant pain’on February 28, 2021 at 5:10 am
All through highschool I wouldn’t nearly miss a whole week off school each month due to the pain and bleeding I experienced.’ ...
- Coronavirus jab may help fight cancer, chronic pain... and even Alzheimer'son February 27, 2021 at 2:21 pm
Scientists have documented unexpected benefits of vaccines for decades - known medically as 'non-specific effects' - but explanations vary between ...
- Desert Pain Specialists bring Intracept, a breakthrough in chronic back pain relief, to Southern Utahon February 25, 2021 at 2:36 pm
CONTRIBUTED CONTENT — Southern Utahns living with persistent and debilitating back pain may at last find relief thanks to a revolutionary new procedure: Intracept. Intracept signals a breakthrough ...
- 'I Got My Chronic Pain Under Control (And Lost 60 Inches!) With A Carnivore-Style Diet'on February 25, 2021 at 5:27 am
I constantly felt fatigued, inflamed, and in pain with every passing day. However, no amount of caffeine, massage therapy, or painkillers made a difference. In addition to my weight-loss problems, I ...
- Home-Based Virtual Reality Reduces Chronic Low Back Painon February 25, 2021 at 1:31 am
By Pat Anson, PNN Editor A new clinical study has found that home-based virtual reality (VR) therapy can significantly reduce pain levels in people suffering from chronic lower back pain. Patients who ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Complete pain relief
- Degradable polymeric vehicles for postoperative pain managementon March 1, 2021 at 4:51 am
Pain management is an extremely important topic both medically and socio-economically. Here the authors offer an overview of the use of degrading polymeric materials for delivery of pharmaceutical ...
- Biden’s economic relief plan will get New York back on its feeton February 24, 2021 at 10:48 am
In the past 20 years alone, we have faced the tragedy of 9/11, the pain of the 2008 financial crisis and the ... Penn Station’s overhaul, the complete redevelopment of the Port Authority Bus Terminal ...
- Beating back pain in dogs: Researchers to test new use for shockwave therapy to bring reliefon February 24, 2021 at 2:30 am
Dogs with chronic lower back pain could eventually find relief from a treatment that already exists. Morris Animal Foundation-funded researchers at The Ohio State University (OSU) recently began a ...
- Livestock Pain Relief and Prevention Market Industry Growth, Price Trends, Market Overview, Forecast To 2027on February 23, 2021 at 6:06 pm
Boehringer Ingelheim, Zoetis, Merck, Elanco, Bayer, Virbac, Ceva Sante Animale, Vetoquinol, Bimeda Animal Health, Chanelle Livestock Pain Relief and Prevention Market by Type (External Use, Internal ...
- Pets Pain Relief and Prevention Market Price Trends, Size, Industry Analysis Report and Forecast 2020-2027on February 23, 2021 at 5:55 pm
Many NSAIDs available in market for pet pain relief that work by reducing the pain-causing inflammation ... type segments and applications (end users). In the complete market engineering process, both ...